Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Swift elimination of undesirable cells is an important feature in tumour suppression and immunity. The tumour suppressor p53 and interferon-alpha and -beta (IFN-alpha/beta) are essential for the induction of apoptosis in cancerous cells and in antiviral immune responses, respectively, but little is known about their interrelationship. Here we show that transcription of the p53 gene is induced by IFN-alpha/beta, accompanied by an increase in p53 protein level. IFN-alpha/beta signalling itself does not activate p53; rather, it contributes to boosting p53 responses to stress signals. We show examples in which p53 gene induction by IFN-alpha/beta contributes to tumour suppression. Furthermore, we show that p53 is activated in virally infected cells to evoke an apoptotic response and that p53 is critical for antiviral defence of the host. Our study reveals a hitherto unrecognized link between p53 and IFN-alpha/beta in tumour suppression and antiviral immunity, which may have therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In response to senesce-inducing stimuli, senescent cells produce, in a cGAS-dependent manner, type I interferons that have pro-senescence and anti-proliferative activities.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
In the citing paper
“Indeed, β-interferons increase ROS production, leading to DNA damage and p53 activation [273,274].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“2a ); ISRE is activated by the IFN-activated transcription factor ISGF3, a heterotrimeric complex consisting of a signal transducer and activator of transcription factor 1 (Stat1), Stat2 and interferon regulatory factor 9 (IRF-9”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Previous studies have shown that p53 -deficient mice show no sign of abnormality in T and B cells, and that they can mount adaptive immune responses normall”
ResultMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodPapillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024 · cited 1×
“Persistent infection with oncogenic HPV types represents a major risk factor for the development of cervical cancer, in which E6 is known to have a critical role (together with another oncoprotein, E7 (ref”
BackgroundDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · cited 1×
“We infer that, similar to DNA damage, ATM activation is caused by changes in the chromatin structure in virus-infected cell”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“We also examined the effect of IFN-β on the DNA damage-induced apoptotic response of MEFs expressing the adenovirus E1A oncoprotein, as it is well known that this response is p53-dependent and critical for tumour suppressio”
BackgroundNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Self-citation
Research works printed but not linked: 1
- Vilcek, J. & Sen, G. S. in Fields Virology 3rd edn (eds Fields, D. M., Knipe, P. M. & Howley, P. M.) 375–399 (Lippincott-Raven, Philadelphia, 1996)
Cited by
Items 101–200 of 867
The importance of p53 pathway genetics in inherited and somatic cancer genomes
Stracquadanio, G., Wang, X., Wallace, M. D., Grawenda, A. M., Zhang, P., Hewitt, J., Zerón-Medina-Cuairán, J., Castro-Giner, F., Tomlinson, I. P. M., Goding, C. R., et al. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.15 · Cited by 150
Type I and II Interferons in the Anti-Tumor Immune Response
Fenton, S. E., Saleiro, D., & Platanias, L. C. (2021) · Cancers · doi:10.3390/cancers13051037 · Cited by 161
“For example, IFNIs upregulate expression of the tumor suppressor p53, reducing cellular transformation [154].”
BackgroundKim, R., Emi, M., Tanabe, K., Uchida, Y., & Toge, T. (2004) · Cancer · doi:10.1002/cncr.20270 · Cited by 161
Shin, Y. C., Nakamura, H., Liang, X., Feng, P., Chang, H., Kowalik, T. F., & Jung, J. U. (2006) · Journal of Virology · doi:10.1128/jvi.80.5.2257-2266.2006 · Cited by 146
Newcomb, D. C., Sajjan, U. S., Nagarkar, D. R., Wang, Q., Nanua, S., Zhou, Y., McHenry, C. L., Hennrick, K. T., Tsai, W. C., Bentley, J. K., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1243oc · Cited by 130
“RV1B exposure induced a robust interferon response, further evidence of viral replication (36).”
BackgroundDual Role of p53 in Innate Antiviral Immunity
Rivas, C., Aaronson, S. A., & Muñoz‐Fontela, C. (2010) · Viruses · doi:10.3390/v2010298 · Cited by 146
Maclaine, N. J., & Hupp, T. R. (2009) · Aging · doi:10.18632/aging.100047 · Cited by 130
Targeting of Toll-like receptors: a decade of progress in combating infectious diseases
Hedayat, M., Netea, M. G., & Rezaei, N. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70099-8 · Cited by 140
The spectrum of sex differences in cancer
Rubin, J. B. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.01.013 · Cited by 125
Bruno, T., Nicola, F. D., Iezzi, S., Lecis, D., D’Angelo, C., Padova, M. D., Corbi, N., Dimiziani, L., Zannini, L., Jekimovs, C., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.012 · Cited by 145
p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines
Taura, M., Eguma, A., Suico, M. A., Shuto, T., Koga, T., Komatsu, K., Komune, T., Sato, T., Saya, H., Li, J.-D., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01202-08 · Cited by 129
Catechin hydrate suppresses MCF-7 proliferation through TP53/Caspase-mediated apoptosis
Alshatwi, A. A. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-167 · Cited by 128
Diversity of Biological Effects Induced by Longwave UVA Rays (UVA1) in Reconstructed Skin
Marionnet, C., Pierrard, C., Golebiewski, C., & Bernerd, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105263 · Cited by 124
PKR , a p53 target gene, plays a crucial role in the tumor-suppressor function of p53
Yoon, C.-H., Lee, E.-S., Lim, D.-S., & Bae, Y.-S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812148106 · Cited by 126
Systems Analysis of a RIG-I Agonist Inducing Broad Spectrum Inhibition of Virus Infectivity
Goulet, M.-L., Olagnier, D. P., Xu, Z.-Y., Paz, S., Belgnaoui, S. M., Lafferty, E. I., Janelle, V., Arguello, M., Paquet, M., Ghneim, K., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003298 · Cited by 134
“Interferon therapy has been used in the clinic for over two decades and has proven effective in the treatment of certain viral infections, mainly Hepatitis B and Hepatitis C [58] , as well as malignancies and autoimmune diseases [68, 69] .”
BackgroundKoromilas, A. E. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.12.007 · Cited by 138
Leaman, D. W., Chawla-Sarkar, M., Jacobs, B., Vyas, K., Sun, Y., Ozdemir, A., Yi, T., Williams, B. R., & Borden, E. C. (2003) · Journal of Interferon & Cytokine Research · doi:10.1089/107999003772084860 · Cited by 121
Inactivating intracellular antiviral responses during adenovirus infection
Weitzman, M. D., & Ornelles, D. A. (2005) · Oncogene · doi:10.1038/sj.onc.1209063 · Cited by 149
“This common goal is evident by the convergence of type I IFN signaling and p53-mediated pathways (Hiscott et al., 2003; Pestka, 2003; Takaoka et al., 2003; MunozFontela et al., 2005).”
BackgroundUnderstanding the mechanisms of viral induced asthma: New therapeutic directions
Hansbro, N. G., Horvat, J. C., Wark, P. A. B., & Hansbro, P. M. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.11.002 · Cited by 139
“They have anti-viral properties and play roles in apoptosis of infected cells and directing adaptive immune responses to clear the virus (Takaoka et al., 2003; Wark et al., 2005) .”
BackgroundHong, S., Mehta, K. P. M., & Laimins, L. A. (2011) · Journal of Virology · doi:10.1128/jvi.05007-11 · Cited by 127
Cross Talk between PML and p53 during Poliovirus Infection: Implications for Antiviral Defense
Pampin, M., Simonin, Y., Blondel, B., Percherancier, Y., & Chelbi‐Alix, M. K. (2006) · Journal of Virology · doi:10.1128/jvi.00031-06 · Cited by 134
Hu, G., Mancl, M. E., & Barnes, B. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0583 · Cited by 122
Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice
Murata, S., Yanagisawa, K., Fukunaga, K., Oda, T., Kobayashi, A., Sasaki, R., & Ohkohchi, N. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01596.x · Cited by 117
Untargeted effects of ionizing radiation: Implications for radiation pathology
Wright, E. G., & Coates, P. J. (2006) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2005.03.035 · Cited by 119
p53 Degradation by a Coronavirus Papain-like Protease Suppresses Type I Interferon Signaling
Yuan, L., Chen, Z., Song, S., Wang, S., Tian, C., Xing, G., Chen, X., Xiao, Z. J., He, F., & Zhang, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.619890 · Cited by 122
“Because virus infection activates p53, this tumor suppressor has been recently introduced as a new component of the cellular antiviral defense mechanism (2).”
BackgroundAlpha‐interferon and its effects on signal transduction pathways
Caraglia, M., Marra, M., Pelaia, G., Maselli, R., Caputi, M., Marsico, S. A., & Abbruzzese, A. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20137 · Cited by 130
“In these experimental conditions p53 gene induction by IFNa/b contributes to tumour suppression, is activated in virally infected cells to evoke an apoptotic response and is critical for antiviral defence of the host (Takaoka et al., 2003).”
BackgroundHerdman, M. T., Pett, M. R., Roberts, I., Alazawi, W. O. F., Teschendorff, A. E., Zhang, X.-Y., Stanley, M. A., & Coleman, N. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl172 · Cited by 113
Epigenetic Silencing of Interferon-κ in Human Papillomavirus Type 16–Positive Cells
Rincon-Orozco, B., Halec, G., Rosenberger, S., Muschik, D., Nindl, I., Bachmann, A., Ritter, T. M., Dondog, B., Ly, R., Bosch, F. X., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0550 · Cited by 116
“This supports the previous finding of a functional cross-talk between type I IFN signal transduction and p53 upregulation (49).”
ResultFrank, A. K., Leu, J. I.-J., Zhou, Y., Devarajan, K., Nedelko, T., Klein-Szanto, A., Hollstein, M., & Murphy, M. E. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01136-10 · Cited by 115
Oncolytic Viruses: Exploiting Cancer's Deal with the Devil
Pikor, L. A., Bell, J. C., & Diallo, J. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.004 · Cited by 125
Interactions between the tumor suppressor p53 and immune responses
Menendez, D., Shatz, M., & Resnick, M. A. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b6386 · Cited by 114
Trp-tRNA synthetase bridges DNA-PKcs to PARP-1 to link IFN-γ and p53 signaling
Sajish, M., Zhou, Q., Kishi, S., Valdez, D. M., Kapoor, M., Guo, M., Lee, S. H., Kim, S., Yang, X., & SCHIMMEL, P. R. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.937 · Cited by 118
Mrass, P., Rendl, M., Mildner, M., Gruber, F., Lengauer, B., Ballaun, C., Eckhart, L., & Tschachler, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1129 · Cited by 112
Interferon, a growing cytokine family: 50 years of interferon research
Chelbi‐Alix, M. K., & Wietzerbin, J. (2007) · Biochimie · doi:10.1016/j.biochi.2007.05.001 · Cited by 112
P53: A Guardian of Immunity Becomes Its Saboteur through Mutation
Agupitan, A. D., Neeson, P., Williams, S., Howitt, J., Haupt, S., & Haupt, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103452 · Cited by 99
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways
Naik, S., & Russell, S. J. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903170653 · Cited by 110
“Thus IFN may preferentially induce quiescence (translational shutdown) in uninfected cells, but apoptosis in infected cells. p53 expression is critical in mediating the pro-apoptotic actions of Type I IFNs [32] but also promotes increased expression of Fas, TRAIL and pro-apoptotic BCl-2 family proteins [33].”
BackgroundInfluentialImpaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer
Hirsch, I., Caux, C., Hasan, U. A., Bendriss‐Vermare, N., & Olive, D. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.07.004 · Cited by 116
The p53-Estrogen Receptor Loop in Cancer
Berger, C. E., Qian, Y., & Chen, X. (2013) · Current Molecular Medicine · doi:10.2174/15665240113139990065 · Cited by 117
Ning, S., Huye, L. E., & Pagano, J. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404260200 · Cited by 118
Baltzis, D., Pluquet, O., Papadakis, A. I., Kazemi, S., Qu, L.-K., & Koromilas, A. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704491200 · Cited by 107
Bhatia, S., Afanasiev, O., & Nghiem, P. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0197-5 · Cited by 108
Interactions of viruses with the cellular DNA repair machinery
Weitzman, M. D., Carson, C. T., Schwartz, R. A., & Lilley, C. E. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.03.018 · Cited by 125
Innate Immunity in the Pathogenesis of Virus-induced Asthma Exacerbations
Johnston, S. L. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-030aw · Cited by 112
Transcriptional and epigenetic regulation of the p53 tumor suppressor gene
Saldaña-Meyer, R., & Recillas-Targa, F. (2011) · Epigenetics · doi:10.4161/epi.6.9.16683 · Cited by 101
Activated cGAS/STING signaling elicits endothelial cell senescence in early diabetic retinopathy
Liu, H., Ghosh, S., Vaidya, T. A., Bammidi, S., Huang, C., Shang, P., Nair, A. P., Chowdhury, O., Stepicheva, N. A., Strizhakova, A., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.168945 · Cited by 113
To kill or be killed: how viruses interact with the cell death machinery
Kaminskyy, V. O., & Zhivotovsky, B. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02222.x · Cited by 116
Cytokine Regulation of Metastasis and Tumorigenicity
Yao, M., Brummer, G., Acevedo, D. S., & Cheng, N. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.005 · Cited by 106
Dauber, B., Heins, G., & Wolff, T. (2004) · Journal of Virology · doi:10.1128/jvi.78.4.1865-1872.2004 · Cited by 113
Gao, J., Senthil, M., Ren, B., Yan, J., Xing, Q., Yu, J., Zhang, L., & Yim, J. H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.156 · Cited by 99
Qu, H.-Q., Jacob, K., Fatet, S., Ge, B., Barnett, D., Delattre, O., Faury, D., Montpetit, A., Solomon, L., Hauser, P., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop001 · Cited by 95
The human papillomavirus E7 oncoprotein as a regulator of transcription
Songock, W. K., Kim, S., & Bodily, J. M. (2016) · Virus Research · doi:10.1016/j.virusres.2016.10.017 · Cited by 109
Wysocka, M., Benoit, B. M., Newton, S. B., Azzoni, L., Montaner, L. J., & Rook, A. H. (2004) · Blood · doi:10.1182/blood-2004-03-1190 · Cited by 104
Interferons α and γ induce p53-dependent and p53-independent apoptosis, respectively
Porta, C., Hadj-Slimane, R., Nejmeddine, M., Pampin, M., Tovey, M. G., Espert, L., Alvarez, S., & Chelbi‐Alix, M. K. (2004) · Oncogene · doi:10.1038/sj.onc.1208204 · Cited by 105
“…are increased in response to treatment with IFNa but not IFNg In agreement with a previous report showing that IFNb induces p53 gene expression (Takaoka et al., 2003), treatment of MCF-7 cells with IFNa, but not IFNg, resulted in a clearcut increase in p53 mRNA expression determined by…”
BackgroundInfluentialImplication of PMLIV in Both Intrinsic and Innate Immunity
Asmi, F. E., Maroui, M. A., Dutrieux, J., Blondel, D., Nisole, S., & Chelbi‐Alix, M. K. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003975 · Cited by 100
Acute lymphoblastic leukemia in adolescents and young adults in Finland
Usvasalo, A., Räty, R., Knuutila, S., Vettenranta, K. K., Harila‐Saari, A. H., Jantunen, E., Kauppila, M., Koistinen, P., Parto, K., Riikonen, P. V., et al. (2008) · Haematologica · doi:10.3324/haematol.12466 · Cited by 98
“IFNA and IFNB also induce the transcription of TP53, contributing to tumor suppression (Takaoka et al. 2003).”
BackgroundPoly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway
Jiang, Q., Wei, H., & Tian, Z. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-12 · Cited by 110
Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds
Selman, M., Rousso, C., Bergeron, A., Son, H. H., Krishnan, R., El-Sayes, N., Varette, O., Chen, A., Bœuf, F. L., Tzelepis, F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.014 · Cited by 98
Schlee, M., Hölzel, M., Bernard, S., Mailhammer, R., Schuhmacher, M., Reschke, J., Eick, D., Marinkovic, D., Wirth, T., Rosenwald, A., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22372 · Cited by 89
Romieu-Mourez, R., Solis, M., Nardin, A., Goubau, D., Baron-Bodo, V., Lin, R., Massie, B., Salcedo, M., & Hiscott, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1279 · Cited by 89
“Cell death induced by IRF-3 or IRF-7 could be mediated by IFN-a/h because IFN-h is known to up-regulate p53 expression and thereby the apoptotic cellular response (33).”
Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells
Obad, S., Brunnström, H., Vallon-Christersson, J., Borg, Å., Drott, K., & Gullberg, U. (2004) · Oncogene · doi:10.1038/sj.onc.1207524 · Cited by 90
“Very recently it was reported that interferon can increase the expression of p53, giving this tumor suppressor a role in signaling downstream of interferon (Pestka, 2003; Takaoka et al., 2003).”
BackgroundInterferon Regulatory Factor 9 Protects Against Cardiac Hypertrophy by Targeting Myocardin
Jiang, D., Luo, Y., Zhang, R., Zhang, X.-D., Chen, H., Zhang, Y., Chen, K., Zhang, S., Fan, G., Liu, P. P., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.02083 · Cited by 91
Genome guardian p53 and viral infections
Sato, Y., & Tsurumi, T. (2012) · Reviews in Medical Virology · doi:10.1002/rmv.1738 · Cited by 97
Catechin hydrate inhibits proliferation and mediates apoptosis of SiHa human cervical cancer cells
Al‐Hazzani, A. A., & Alshatwi, A. A. (2011) · Food and Chemical Toxicology · doi:10.1016/j.fct.2011.09.023 · Cited by 90
Type I interferons and related pathways in cell senescence
Frisch, S. M., & MacFawn, I. P. (2020) · Aging Cell · doi:10.1111/acel.13234 · Cited by 85
“Clues may potentially be found in earlier reports, including (a) IRF5 or IRF7 over-expression can induce DDR-dependent senescence (Li et al., 2008), albeit through mechanisms not yet understood; (b) IFN-I increases cellular ROS, potentially damaging DNA (Moiseeva et al., 2006; Takaoka et al., 2003).”
BackgroundResultGene therapy for hepatocellular carcinoma using sonoporation enhanced by contrast agents
Sakakima, Y., Hayashi, S., Yagi, Y., Hayakawa, A., Tachibana, K., & Nakao, A. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700850 · Cited by 88
Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming
Torrano, J., Emran, A. A., Hammerlindl, H., & Schaider, H. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0644-y · Cited by 95
Caulin, A. F., Graham, T. A., Wang, L.-S., & Maley, C. C. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0222 · Cited by 87
Moschella, F., Torelli, G. F., Valentini, M., Urbani, F., Buccione, C., Petrucci, M. T., Natalino, F., Belardelli, F., Foà, R., & Proietti, E. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3666 · Cited by 83
Kang, D. Y., Sp, N., Jo, E. S., Rugamba, A., Hong, D. Y., Lee, M. H., Yoo, J., Liu, Q., Jang, K., & Yang, Y. M. (2020) · Cancers · doi:10.3390/cancers12030727 · Cited by 87
Toll-Like Receptor Transcriptome in the HPV-Positive Cervical Cancer Microenvironment
DeCarlo, C. A., Rosa, B. A., Jackson, R., Niccoli, S., Escott, N. G., & Zehbe, I. (2011) · Clinical and Developmental Immunology · doi:10.1155/2012/785825 · Cited by 97
Li, Q., Kawamura, K., Ma, G., Iwata, F., Numasaki, M., Suzuki, N., Shimada, H., & Tagawa, M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.10.002 · Cited by 88
“Type I IFNs enhance p53 expression and favour for apoptosis induction in the cells with intact p53 pathways.(26,27) It is currently unknown whether IFN-ks also increase p53 expression but the present study showed that the p53 status of the oesophageal carcinoma cells was not directly correlated with the IFN-k1-mediate…”
BackgroundKinpara, S., Kijiyama, M., Takamori, A., Hasegawa, A., Sasada, A., Masuda, T., Tanaka, Y., Utsunomiya, A., & Kannagi, M. (2013) · Retrovirology · doi:10.1186/1742-4690-10-52 · Cited by 81
Plasmacytoid Dendritic Cells in HIV Infection
O’Brien, M. P., Manches, O., & Bhardwaj, N. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4433-6_3 · Cited by 96
IRF-5 Is a Mediator of the Death Receptor-induced Apoptotic Signaling Pathway
Hu, G., & Barnes, B. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804744200 · Cited by 85
Watanabe, T., Sudoh, M., Miyagishi, M., Akashi, H., Arai, M., Inoue, K., Taira, K., Yoshiba, M., & Kohara, M. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302734 · Cited by 85
New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-?) treatment of human cancer
Tagliaferri, P., Caraglia, M., Budillon, A., Marra, M., Vitale, G., Viscomi, C., Masciari, S., Tassone, P., Abbruzzese, A., & Venuta, S. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0549-1 · Cited by 98
Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy
Fuchs, S. Y. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0117 · Cited by 80
Whelan, J., Seddon, B. M., & Perisoglou, M. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0020-y · Cited by 85
Müller, C. R., Smeland, S., Bauer, H. C. F., Sæter, G., & Strander, H. (2005) · Acta Oncologica · doi:10.1080/02841860510029978 · Cited by 82
Klampfer, L., Huang, J., Corner, G., Mariadason, J., Arango, D., Sasazuki, T., Shirasawa, S., & Augenlicht, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304721200 · Cited by 79
Choubey, D., & Panchanathan, R. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.002 · Cited by 89
The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV
Hemmat, N., Asadzadeh, Z., Ahangar, N. K., Alemohammad, H., Najafzadeh, B., Derakhshani, A., Baghbanzadeh, A., Baghi, H. B., Javadrashid, D., Najafi, S., et al. (2021) · Archives of Virology · doi:10.1007/s00705-021-04958-7 · Cited by 98
Type I Interferon Controls Propagation of Long Interspersed Element-1
Yu, Q., Carbone, C. J., Katlinskaya, Y. V., Zheng, H., Zheng, K., Luo, M., Wang, P. J., Greenberg, R. A., & Fuchs, S. Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612374 · Cited by 76
“Given the ability of recombinant IFNβ to induce p53 (39,40) and the role of p53 in IFNmediated anti-viral effects (41), it is also possible that the modes of negative regulation elicited by IFN may differ between retrotransposons and active viruses.”
BackgroundDouble-edged effects of interferons on the regulation of cancer-immunity cycle
Zhang, X., Wang, S., Zhu, Y., Zhang, M., Zhao, Y., Yan, Z., Wang, Q., & Li, X. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929005 · Cited by 85
Impaired airway epithelial cell responses from children with asthma to rhinoviral infection
Kicic, A., Stevens, P. T., Sutanto, E. N., Kicic‐Starcevich, E., Ling, K., Looi, K., Martinovich, K. M., Garratt, L. W., Iosifidis, T., Shaw, N. C., et al. (2016) · Clinical & Experimental Allergy · doi:10.1111/cea.12767 · Cited by 84
“protein pre and post viral infection which has also been reported by others [30], but were able”
BackgroundResistance to viral infection of super p53 mice
Muñoz‐Fontela, C., García, M. Á., García-Cao, I., Collado, M., Arroyo, J., Estéban, M., Serrano, M., & Rivas, C. (2005) · Oncogene · doi:10.1038/sj.onc.1208477 · Cited by 86
“The magnitude of the increase in the amount of virus produced from p53 / MEFs compared to control WTMEFs was similar to that reported by Takaoka et al. (2003).”
BackgroundResultInfluentialDembinski, J. L., Wilson, S. M., Spaeth, E. L., Studeny, M., Zompetta, C., Samudio, I., Roby, K., Andreeff, M., & Marini, F. C. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2012.10.003 · Cited by 77
“IFN-b has been shown to boost the transcription of the p53 gene and increase its protein levels (41).”
Klass, C. M., Krug, L. T., Pozharskaya, V. P., & Offermann, M. K. (2005) · Blood · doi:10.1182/blood-2004-09-3569 · Cited by 84
Dash, S., Chava, S. P., Aydın, Y., Chandra, P. K., Ferraris, P., Chen, W., Balart, L. A., Wu, T., & Garry, R. F. (2016) · Viruses · doi:10.3390/v8050150 · Cited by 81
Interferon regulatory factor 9 is critical for neointima formation following vascular injury
Zhang, S., Zhu, L., Chen, H., Zhang, R., Zhang, P., Jiang, D.-S., Gao, L., Tian, S., Wang, L., Zhang, Y., et al. (2014) · Nature Communications · doi:10.1038/ncomms6160 · Cited by 82
Cell and tissue responses to genotoxic stress
Coates, P. J., Lorimore, S. A., & Wright, E. G. (2005) · The Journal of Pathology · doi:10.1002/path.1701 · Cited by 85
“Conversely, interferon-α and -β induce transcription of the p53 gene and boost the p53 response to stress [188].”
BackgroundProphylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease
Ban, T., Kikuchi, M., Sato, G. R., Manabe, A., Tagata, N., Harita, K., Nishiyama, A., Nishimura, K., Yoshimi, R., Kirino, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24609-4 · Cited by 80
Self-citationWakabayashi, T., Natsume, A., Hashizume, Y., Fujii, M., Mizuno, M., & Yoshida, J. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1160 · Cited by 76
Kim, M., Williamson, C. T., Prudhomme, J., Bebb, D. G., Riabowol, K. T., Lee, P. W. K., Lees‐Miller, S. P., Mori, Y., Rahman, M. M., McFadden, G., et al. (2010) · Oncogene · doi:10.1038/onc.2010.137 · Cited by 76
“…in cells already highly responsive to the virus, other studies have shown that p53 contributes to innate immunity by enhancing interferon-dependent antiviral activity independent of its functions as a proapoptotic and tumor suppressor gene (Takaoka et al., 2003; Muñoz-Fontela et al., 2008).”
BackgroundLu, S., Pardini, B., Cheng, B., Naccarati, A., Huhn, S., Vymetalkova, V. P., Vodičková, Ľ., Büchler, T., Hemminki, K., Vodička, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111061 · Cited by 80
“The two type I IFNs, IFNA and IFNB, have been reported to have an effect on tumor suppression and antiviral immune defense through induction of p53 responses [13].”
InfluentialThe implication of SUMO in intrinsic and innate immunity
Hannoun, Z., Maarifi, G., & Chelbi‐Alix, M. K. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.04.003 · Cited by 83
Solis, M., Goubau, D., Romieu, R., Génin, P., Civas, A., & Hiscott, J. B. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.002 · Cited by 82
Role of IFI 16 in cellular senescence of human fibroblasts
Xin, H., Pereira‐Smith, O. M., & Choubey, D. (2004) · Oncogene · doi:10.1038/sj.onc.1207836 · Cited by 81
“Of note, expression of both p53 (Takaoka et al., 2003) and p21WAF1 (Sangfelt et al., 1999) is upregulated by IFNs.”
BackgroundGuo, C.-J., Zhang, Y.-F., Yang, L., Yang, X., Wu, Y., Liu, D., Chen, W., Weng, S., Yu, X., & He, J. (2009) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2009.06.001 · Cited by 75
Metadata
- Authors
- Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., & Taniguchi, T.
- Affiliations
- The University of Tokyo (JP)
- University of Vienna (AT)
- Sapporo Medical University (JP)
- Corresponding author
- Taniguchi, Tadatsugu
- ORCID
- Venue
- Nature
- Published
- 2003-07
- Volume
- 424
- Issue
- 6948
- Pages
- 516-523
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2119885778
- Cited by
- 847
- References
- 51
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 20 · 2023: 25 · 2022: 22 · 2021: 32 · 2020: 41 · 2019: 40 · 2018: 21 · 2017: 38 · 2016: 50 · 2015: 44 · 2014: 40 · 2013: 46 · 2012: 38
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Boehringer Ingelheim Japan
- Senri Life Science Foundation
- Kanae Foundation for the Promotion of Medical Science
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, type I interferon, interferon signaling, tumor suppression, antiviral defense, apoptosis, viral infection, cancer therapy
- MeSH terms
- Animals, Cell Transformation, Neoplastic, DNA-Binding Proteins, Humans, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Vesicular stomatitis Indiana virus, Signal Transduction, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Interferon-alpha, Interferon-beta, Apoptosis, Response Elements, Interferon-Stimulated Gene Factor 3, Interferon-Stimulated Gene Factor 3, gamma Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.